WE’RE MOVING! NEW ADDRESS AND PHONE NUMBERS …MORE


WELCOME TO ONCOSCIENCE

ABOUT US

Oncoscience AG develops therapeutic options for rare diseases in oncology.

CLICK HERE FOR MORE INFO


ONCOLOGY

ONCOLOGY AND ORPHAN DRUGS

Cancer is one of the leading causes of death worldwide and e.g. in Germany the second leading cause of death after cardiovascular diseases.

CLICK HERE FOR MORE INFO

NEWS

Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba

Oncoscience | April 7th, 2016

At this global clinical development meeting, more than 150 researches from over 20 countries discuss the latest results ...

Innokeys Pte. Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG

Oncoscience | July 22nd, 2015

The acquisition enables Innokeys to fully lead clinical and commercial development of Nimotuzumab in Europe. Transactio...

Oncoscience AG and GenIlac agree on cooperation terms in Turkey

Oncoscience | July 7th, 2010

Oncoscience, Wedel and GenIlac, Ankara agree on cooperation in Turkey for Nimotuzumab(Theraloc®), an EGFr antibody, whi...